BCBing Chen

Bing Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bing Chen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Xu

    Center for Global Public Health Chinese Center for Disease Control and Prevention Beijing China

    2 shared publications
  • Li‐Jian Pei

    National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and Prevention Beijing China

    2 shared publications
  • Ning Han

    Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Anhui, China

    2 shared publications
  • Zhong‐Hui Ma

    Department of Communicable and Endemic Disease Control and Prevention Fangshan District Center for Disease Control and Prevention in Beijing Beijing China

    2 shared publications
  • Ai-Hua Wang

    Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Anhui, China

    1 shared publication
  • Chu Qiu-Ju

    Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou, PR China

    1 shared publication

Latest Publications

  • Open Access

    The epidemic characteristics of Mycoplasma pneumoniae infection among children in Anhui, China, 2015–2023

    by Bing Chen, Ling-Yu Gao, Qiu-Ju Chu, Ting-Dong Zhou, Yang Tong, Ning Han, Ai-Hua Wang, Qiang Zhou

    The number of pediatric respiratory tract infection cases in China has significantly increased this year, and Mycoplasma pneumoniae is one of the main pathogens. This study aimed to investigate the epidemiological characteristics of M. pneumoniae in children in the Anhui region and to provide evidence for the prevention and control strategies of M. pneumoniae in children in this region. A total of 66,488 pediatric patients with respiratory tract infection were enrolled from January 2015 to November 2023 in this study. The results of this study exhibited that M. pneumoniae infection in the Anhui region was characterized by a high positive rate during 2021–2023, especially this year is considered a year of pandemic for M. pneumoniae infection. Moreover, the positive rate of M. pneumoniae in female children is significantly higher than in male children, and the infection rate of M. pneumoniae in children increases significantly with age, particularly in school-aged children. IMPORTANCE: The number of pediatric respiratory tract infection cases in China has significantly increased this year, and Mycoplasma pneumoniae is one of the main pathogens. This study aimed to investigate the epidemiological characteristics of M. pneumoniae in children in the Anhui region and provide evidence for the prevention and control strategies of M. pneumoniae in children in this region.


  • Open Access

    Routine blood parameters as auxiliary diagnostic tools for Mycoplasma pneumoniae infection in children

    by Chu Qiu-Ju, Gao Ling-Yu, Zhou Ting-Dong, Tong Yang, Han Ning, Wang Ai-Hua, Hu Huai-Lou, Zhou Qiang, Chen Bing

    Introduction. Recently, the incidence of Mycoplasma pneumoniae (M. pneumoniae) infection in children has been increasing annually. Early differential diagnosis of M. pneumoniae infection can not only avoid the abuse of antibiotics, but also is essential for early treatment and reduction of transmission. Gap statement. The change of routine blood parameters may have important clinical significance for the diagnosis of M. pneumoniae infection, but it has not been reported so far. Aim. This study aims to establish a predictive model for M. pneumoniae infection and explore the changes and clinical value of routine blood parameters in children with M. pneumoniae infection, serving as auxiliary indicators for the diagnosis and differentiation of clinical M. pneumoniae infection. Methodology. A total of 770 paediatric patients with respiratory tract infections were enrolled in this study, including 360 in the M. pneumoniae group, 40 in the SARS-CoV-2 group, 200 in the influenza A virus group, and 170 in the control group. The differences of routine blood parameters among all groups were compared, and risk factors were analysed using multivariate logistics analysis, and the diagnostic efficacy of differential indicators using ROC curves. Results. This study revealed that Mono% (OR: 3.411; 95% CI: 1.638–7.102; P=0.001) was independent risk factor associated with M. pneumoniae infection, and Mono% (AUC=0.786, the optimal cutoff at 7.8%) had a good discriminative ability between patients with M. pneumoniae infection and healthy individuals. Additionally, Mono% (OR: 0.424; 95% CI: 0.231–0.781; P=0.006) and Lymp% (OR: 0.430; 95% CI: 0.246–0.753; P=0.003) were independent risk factors for distinguishing M. pneumoniae infection from influenza A virus infection, and the Lymp% (AUC=0.786, the optimal cutoff at 22.1%) and Net% (AUC=0.761, the optimal cutoff at 65.2%) had good discriminative abilities between M. pneumoniae infection and influenza A infection. Furthermore, platelet distribution width (OR: 0.680; 95% CI: 0.538–0.858; P=0.001) was independent risk factor for distinguishing M. pneumoniae infection from SARS-CoV-2 infection. Meanwhile, the ROC curve demonstrated that PDW (AUC=0.786, the optimal cutoff at 15%) has a good ability to differentiate between M. pneumoniae infection and SARS-CoV-2 infection. Conclusion. This study demonstrates that routine blood parameters can be used as auxiliary diagnostic indicators for M. pneumoniae infection and provide reference for the diagnosis and differentiation of clinical M. pneumoniae infection.


  • Comparison of effectiveness and cost of different HCV testing strategies in high‐risk populations in China

    by Bing Chen, Bing Xu, Hai‐Yan Cui, Zhong‐Hui Ma, Wen‐Hui Guo, Li‐Jian Pei, Wen‐Ge Xing

    High‐risk populations are the predominant populations affected by hepatitis C virus (HCV) infection, and there is an urgent need for efficient and cost‐effective HCV testing strategies for high‐risk populations to identify potential undiagnosed HCV‐infected individuals. This study compared several commonly used testing strategies and conducted effectiveness and cost analysis to select the appropriate testing strategy for diagnosing HCV infection in high‐risk populations. Among the 2093 samples from high‐risk populations in this study, 1716 were HCV negative, 237 were current HCV infection, 137 were past HCV infection, and three were acute early HCV infection. It was found that out of 237 patients with HCV current infection, Strategy A could detect 225 cases, with a missed detection rate of 5.06%, and the total cost was 33 299 RMB. In addition, Strategy B could detect 237 cases of current HCV infection, and the HCV missed detection rate was 0.00%, and the total cost was 147 221 RMB. While 137 cases of past HCV infection could be distinguished by strategy C, but 14 cases with current HCV infection were missed, with an HCV‐positive missed detection rate of 5.91%, and the total cost for Strategy C was 43 059 RMB. In conclusion, in high‐risk populations, the HCV positivity rate is typically higher. If feasible, the preferred approach is to directly conduct HCV RNA testing, which effectively minimizes the risk of missing cases. However, in situations with limited resources, it is advisable to initially choose a highly sensitive method for anti‐HCV screening, followed by HCV RNA testing on reactive samples.


  • Comparison of immune responses in children with infectious mononucleosis caused by Epstein–Barr virus at different infection stages

    by Bing Chen, Ning Han, Ling‐Yu Gao, Ting‐Dong Zhou, Hao Zhang, Pei He, Qiang Zhou

    Introduction: Infectious mononucleosis (IM) is a common infectious disease in children mainly caused by Epstein–Barr virus (EBV) infection, followed by abnormal immune response, and resulting in serious complications. However, there are few clinical analyses of immune responses in children with IM at different stages.Methods: This study combined EBV serological test and EBV DNA test to diagnose the infection status of children with IM, and the infection status was divided into primary acute IM infection (AIM), primary late IM infection (LIM) and reactivation IM infection (RIM).Results: The results revealed that the absolute numbers of leukocytes and CD8+ T lymphocytes in primary IM infection were significantly higher than those in reactivation infection, while the frequencies of CD4+ T lymphocytes and B cells were significantly lower than those in reactivation infection. In addition, the activities of ALT, AST, α‐HBDH and LDH in liver function indicators in primary infection were significantly increased compared with reactivation infection. Similarly, the EBV DNA levels of the primary infection were significantly higher than that of the reactivation infection.Conclusion: There are differences in immune response at different stages of infection, which can provide guidance for effective treatment in children with IM infection.


  • Evaluation of seven rapid diagnostic tests for detection of hepatitis C virus antibodies in China

    by Bing Chen, Zhong‐Hui Ma, Bing Xu, Hao Chang, Xiao‐Xia He, Li‐Jian Pei, Ya‐Nan Ren, Wen‐Ge Xing

    Rapid diagnostic tests as an attractive alternative to enzyme immunoassay could identify hepatitis C virus (HCV) infected persons more expeditiously. The availability of high performing and quality‐assured rapid diagnostic tests are essential to scale‐up HCV screening. The study was undertaken to evaluate the performance of seven domestic HCV rapid diagnostic tests kits. The kits were evaluated by using HCV serum panels, including HCV basic panel, analytical specificity panel, mixed titre performance panel, characteristic panel, seroconversion panel, and genotype qualification panel. The results showed that clinical sensitivity, clinical specificity and analytical specificity of seven rapid diagnostic tests kits ranged from 94% (95% CI: 83.2–98.6) to 100% (95% CI: 91.5–100). Furthermore, specimens with HCV genotypes 1b, 2a, 3a, 4a, 5a, 6 could be detected by HCV rapid diagnostic tests kits, whereas specimens with genotypes 1a and 2b could not be detected. Additionally, most HCV rapid diagnostic tests kits had great performance in diagnosing different titres and/or different bands samples, but some low S/CO value specimens may not be fully detected by few rapid diagnostic test kits. In conclusion, seven HCV rapid diagnostic tests reagents presented high sensitivity, specificity, good anti‐interference and detection ability of early infection, which could meet the requirements of clinical HCV antibody screening.